Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California-San Francisco
San Francisco, California, United States
- Florida Cancer Specialists-South
Fort Myers, Florida, United States
- Florida Hospital Cancer Insitute
Orlando, Florida, United States
- Florida Cancer Specialists-North
St. Petersburg, Florida, United States
- Ingalls Cancer Research Center
Harvey, Illinois, United States
- Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
- South Carolina Oncology Associates
Columbia, South Carolina, United States
- Tennessee Oncology - Chattanooga
Chattanooga, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- the Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2013
- Primary completion
- 31 Mar 2016
- Completion
- 31 Mar 2016
- Last update posted
- 16 May 2017
- Registered enrollment
- 132
- Registry id
- NCT01844817
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.